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MHC class I molecules (HLA-I in humans) present peptides derived from endogenous proteins to CTLs. Whereas the peptide-
binding specificities of HLA-A and -B molecules have been studied extensively, little is known about HLA-C specificities. Combining
a positional scanning combinatorial peptide library approach with a peptide–HLA-I dissociation assay, in this study we present
a general strategy to determine the peptide-binding specificity of any MHC class I molecule. We applied this novel strategy to 17 of
the most common HLA-C molecules, and for 16 of these we successfully generated matrices representing their peptide-binding
motifs. The motifs prominently shared a conserved C-terminal primary anchor with hydrophobic amino acid residues, as well as one or
more diverse primary and auxiliary anchors at P1, P2, P3, and/or P7. Matrices were used to generate a large panel of HLA-C–specific
peptide-binding data and update our pan-specific NetMHCpan predictor, whose predictive performance was considerably improved
with respect to peptide binding to HLA-C. The updated predictor was used to assess the specificities of HLA-C molecules, which were
found to cover a more limited sequence space than HLA-A and -B molecules. Assessing the functional significance of these new tools,
HLA-C*07:01 transgenic mice were immunized with stable HLA-C*07:01 binders; six of six tested stable peptide binders were
immunogenic. Finally, we generated HLA-C tetramers and labeled human CD8+ T cells and NK cells. These new resources should
support future research on the biology of HLA-C molecules. The data are deposited at the Immune Epitope Database, and the updated
NetMHCpan predictor is available at the Center for Biological Sequence Analysis and the Immune Epitope Database. The Journal of
Immunology, 2014, 193: 4790–4802.
T
he major histocompatibility gene complex is generically
known as the MHC system and in humans as the HLA
system. It encodes a highly diverse set of important im-
munological proteins, including the classical MHC (or HLA) class
I (MHC-I) and II Ags. The major function of classical HLA class I
(HLA-I) molecules is to sample peptides derived from cytosolic
proteins and present them to CD8+ CTLs, thereby allowing CTLs
to survey the ongoing protein metabolism of our cells and monitor
it for the presence of intracellular pathogens. In a complementary
function, some HLA-I molecules serve as ligands for killer Ig–
related receptors (KIRs), thereby allowing NK cells to survey our
cells for HLA-I expression and counteract any pathogen, which, in
an attempt to reduce HLA-I expression and escape CTL-mediated
immune reactions, might interfere with Ag processing and pre-
sentation. This enforces Ag presentation and assures that our
protein metabolism is subject to CTL scrutiny at all times.
The HLA system is polygenic and extremely polymorphic. For
HLA-I Ags, there are three classical isotypes corresponding to the
three loci, HLA-A, -B, and -C. Each of these loci has a very large
number of unique alleles encoding a great number of variants, or
allotypes. Currently, the numbers of known HLA-A, -B, and -C
alleles are 1833, 2459, and 1507, respectively (http://www.ebi.ac.
uk/ipd/imgt/hla/stats.html; accessed: March 2014). The polymor-
phic residues are primarily concentrated at the lining of the
peptide-binding site where they determine the shape and func-
tionality (i.e., the specificity) of the site. Owing to the polygenic
and polymorphic nature of the HLA system, each individual
presents a unique selection of peptides derived from our cells’
protein metabolism. This individualizes the specificity of our
cellular immune systems and reduces the risk of developing
population-wide microbial escape mutants.
Peptide binding is a fundamental requirement for the proper
folding, expression, and function of classical HLA molecules.
Obviously, the final outcome depends on the ensemble of all these
processes, but peptide binding is by far the dominant factor in
determining which peptides are naturally presented. Thus, under-
standing the specificities of peptide interactions with HLA-I mol-
ecules is essential for our understanding of how the CTL and the NK
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systems operate. Currently, our knowledge of the peptide-binding
specificity of HLA-I molecules differs considerably between the
three HLA-I isotypes. A total of some 112,000 and 53,500 examples
of HLA-A and -B interactions representing 48 and 66 different
HLA-A and -B allotypes, respectively, are currently registered in the
Immune Epitope Database (IEDB; www.iedb.org; accessed March
2014). These data have enabled the generation of accurate quanti-
tative predictors of peptide binding to HLA-A and -B molecules
(including but not limited to Refs. 1–3). With this coverage of
allotypes, it has been possible to leverage the data from different
HLA-I allotypes and generate pan-specific predictors such as the
NetMHCpan, which is a reasonably accurate predictor even for
allotypes and species that have not yet been described experimen-
tally (4, 5). In contrast, much fewer data are available for HLA-C
where only some 1200 examples of peptide interactions represent-
ing merely eight different HLA-C allotypes have been registered at
the IEDB. Therefore, predictions of peptide binding to HLA-C are
less accurate, and it is more difficult to extend pan-specific pre-
dictions to all allotype members of this isotype. This lack of in-
formation about the specificity of HLA-C molecules effectively
limits our understanding of this isotype and its role in human im-
munity.
There is no doubt that HLA-C merits considerable interest. It
appears to be particularly adapted for recognition by KIR mole-
cules of the NK cells. Whereas fewer than half of the HLA-A and
-B allotypes serve as KIR ligands, and this only in conjunction with
a few peptides, all HLA-C allotypes express KIR ligands, either in
the form of the C1 or C2 epitopes, and this in conjunction with
many different peptides (6–9). In another function, it has been
suggested that the interaction of uterine NK cells with HLA-C,
which is uniquely expressed on fetal extravillous trophoblast, is
important for successful placentation (10, 11). Finally, the poly-
morphism of the HLA-C isotype indicates that it is capable of
binding a diverse repertoire of peptides in keeping with it also
having an important role in Ag presentation and generation of
CTL responses. Indeed, HLA-C molecules are known to bind
peptides of microbial origin and present them to CTLs [e.g., HIV
(12–14) and CMV (15)]. The recent discovery of the ability of
HIV-1 Nef proteins to selectively downregulate HLA-A and HLA-
B, but not HLA-C, expression (16) suggests that HLA-C may play
a unique role in Ag presentation.
In this study, we have developed a general approach to address
the specificity of any hitherto unknown MHC-I molecule. Gen-
erating a panel of highly active, recombinant HLA-C allotype
molecules, we have determined the peptide-binding motifs of 16
HLA-C molecules. All molecules were found to have a primary
anchor at the peptide C terminus with preferences for hydrophobic
residues; N-terminally, strong anchors were generally observed in
P2 and P3, and auxiliary anchors were sometimes seen in P1 and
P7. We have applied this novel approach to identify and measure
the binding of a panel of individual peptides to these HLA-C
allotypes. The resulting data were used to update our pan-
specific predictor, NetMHCpan, thereby significantly improving
the accuracy of this predictor. The pan-specific predictor was used
to analyze the specificity of all HLA-C allotypes, and the results
indicate that the peptide-binding repertoire of HLA-C is more
limited compared with the repertoires of HLA-A and -B. Finally,
we validated these tools by identifying a panel of HLA-C*07:01–
binding peptides and demonstrated that six of six stable peptides
were immunogenic in an HLA-C*07:01 transgenic mouse model.
The updated NetMHCpan predictor should support further inves-
tigations into the nature of HLA-C–mediated immunity, including
both CTL and NK activity. It is available at the Web sites http://
www.cbs.dtu.dk/services/NetMHCpan and http://www.iedb.org/.
Materials and Methods
Peptides
All peptides were purchased from Schafer-N (Copenhagen, Denmark). Briefly,
peptides were synthesized using standard Fmoc (9-fluorenylmethyloxycarbonyl)
chemistry. Synthesized peptides were purified by reverse-phase HPLC
to .80% purity and validated by mass spectrometry. Positional scanning
combinatorial peptide libraries (PSCPL) were synthesized as previously
described (17). Briefly, eight of nine positions comprised an equimolar
pool of 19 of the 20 natural amino acids (i.e., excluding cysteine), whereas
the remaining position comprised 1 of the 20 natural amino acids
(i.e., including cysteine), thereby interrogating the position-specific effect
of this latter amino acid. In one synthesis, the amino acid pool was used in
all nine positions. The library therefore consisted of (20 3 9) +1, or 181
individual peptide libraries (where X denotes the random incorporation of
an amino acid from the mixture, and the fixed amino acid and its identity is
indicated by the single letter amino acid abbreviation): 20 PSCPL sublibraries
describing position 1, AX8, CX8, DX8, ….YX8; 20 PSCPL sublibraries de-
scribing position 2, XAX7, XCX7, XDX7, …. XYX7; and so forth to 20
PSCPL sublibraries describing position 9, X8A, X8C, X8D, …. X8Y; and fi-
nally a completely random peptide library, X9.
Protein production
Recombinant biotinylated MHC-I molecules were produced as previously
described (18–20). Briefly, relevant HLA-encoding genes (a1a2a3, resi-
dues 1–275) were cloned into a pET28a expression vector already con-
taining a biotin signal peptide and a histidine affinity tag. For HLA-C
alleles encoding cysteine in residue 1, this was mutated to glycine to
prevent unwanted disulfide formation. Constructs were validated by DNA
sequencing and transformed into Escherichia coli BL21(DE3) expression
strains carrying the pACYC vector encoding BirA for in vivo biotinylation.
Transformed cells were grown in a 2.5-l Infors fermentor. When the cell
density reached OD600 of 25, protein production was induced with iso-
propyl b-D-thiogalactoside. The cells were harvested after 3 h and lysed by
high-pressure cell disruption. Inclusion bodies containing recombinant
MHC-I were isolated by centrifugation and washed to remove cell debris.
Inclusion bodies were extracted into Tris-buffered 8 M urea (pH 8.0), and
HLA molecules were purified under denaturing and nonreducing con-
ditions by successive immobilized metal affinity, hydrophobic interaction,
and size exclusion chromatography. Isolated HLA molecules were stored
at 224˚C until use.
Native recombinant b2-microglobulin (b2m) was produced as described
previously (21).
Radiolabeling
Recombinant b2m was radiolabeled with [
125I] according to the chloramine-
T labeling procedure (22). At room temperature, 20 mg b2m was mixed with
1 mCi [125I] (PerkinElmer, NEZ033A005MC) and 5 mg chloramine-T
(Sigma-Aldrich, C9887) in a total volume of 65 ml. The reaction was
stopped after 1 min by addition of 5 ml metabisulfite (1 mg/ml). Free iodine
was removed by Sephadex G10 size exclusion chromatography using a 4-ml
column equilibrated and eluted in PBS/2% ethanol/0.1% azide. Fractions
(200 ml) were collected and peak fractions containing radioactivity were
pooled. The radioactivity incorporated was measured on a gamma counter
(Packard Cobra 5010). Radiolabeled b2m was stored at 4˚C for #4 wk.
Determining peptide-binding motifs by a scintillation
proximity-based dissociation assay
Nonameric peptide-binding motifs were determined for HLA-C*01:02,
-C*02:02, -C*03:02, -C*03:03, -C*03:04, -C*04:01, -C*05:01, -C*06:02,
-C*07:01, -C*07:02, -C*07:04, -C*08:01, -C*08:02, -C*12:03, -C*14:02,
-C*15:02, and -C*16:01 using a recently developed scintillation proximity
assay (SPA)–based peptide–MHC-I dissociation assay (23) in combination
with nonameric PSCPL (17). In 384-well streptavidin-coated FlashPlate
HTS Plus microplates (PerkinElmer, SMP410), recombinant biotinylated
MHC-I H chain in 8 M urea was diluted at least 100 times (to 50 nM) into
PBS/0.1% Lutrol F68 containing 78 mg/ml (78 mM) of each sublibrary
with 2–10 nM [125I]-radiolabeled b2m in PBS, giving a total volume of 60
ml/well. The plates were sealed and incubated overnight at 18˚C. Disso-
ciation was started by adding 10 ml/well unlabeled b2m in PBS (1.4 mM,
final concentration 200 nM) to prevent reassociation of any dissociated
radiolabeled b2m, and transferring the plate to a TopCount NXT scin-
tillation counter set to 37˚C. The amount of labeled b2m still associated
with HLA-C was measured continuously for 24 h as previously de-
scribed (23).
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Analysis of PSCPL data
The area under the dissociation curve (AUC) was calculated after background
subtraction by summarizing the cpm from 0 to 24 h. The relative binding
(RB), that is, the relative contribution of each sublibrary to peptide binding,
was calculated according to the following equation: RB = AUCsublibrary/
AUCX9. The RB values of each amino acid in a given position were sum-
marized and normalized so the sum equals 20 (17). An anchor position (AP)
value for each peptide position, defining the relative contribution of this
position to peptide binding, was calculated as:
AP ¼ +
20
i¼1
ð12RBsublibraryÞ2
Sequence logos describing the amino acid binding specificity captured by
the PSCPL were calculated using the Seq2Logo sequence logo generator
(24). In short, the RB values at each peptide position were normalized
by the sum of the RB values at the given position. This normalized
PSCPL matrix was submitted to the Seq2Logo server, and binding motif
was visualized as a p-weighted Kullback–Leibler logo generated using
a flat amino acid background distribution (i.e., all amino acids are as-
sumed to be found with an equal frequency). In this type of logo, anchor
positions are characterized by a tall stack of letters, amino acids pre-
sented on the positive y-axis are enriched in peptide binders, and amino
acids on the negative y-axis are depleted from peptide binders.
Peptide–MHC-I-binding assay
Peptide affinities of HLA-Cmolecules were determined using a luminescent
oxygen channeling immunoassay (25). Briefly, peptides were dissolved in
PBS/0.1% Lutrol F68 by sonication for 10 min. Peptides were titrated in
384-well microplates using a Microlab STAR liquid handling robot
(Hamilton Robotics). Recombinant, denatured HLA-C H chain was diluted
into PBS/0.1% Lutrol F68/100 mM Tris/maleate (pH 6.6) containing
prefolded, recombinant b2m on ice. The H chain/b2m mix was added 1:1
to the peptide titrations and incubated for 48 h at 18˚C to allow peptide–
MHC-I complex folding. After complex folding, samples were transferred
to 384-well OptiPlates, and streptavidin-coated donor beads (PerkinElmer,
6760002) and W6/32-conjugated acceptor beads (PerkinElmer, 6762001,
in-house conjugated with W6/32) diluted in PBS/0.1% Lutrol F68 were
added to a final concentration of 5 mg/ml each. The OptiPlates were in-
cubated overnight and luminescence was measured in an EnVision 2103
multilabel reader.
Bioinformatics analysis of the peptide-binding specificity of
HLA-C allotypes
A set of 121 frequent HLA-A, -B, and -C alleles present in the European
population was identified using the dbMHC database (http://www.ncbi.nlm.
nih.gov/gv/mhc/) using an allele frequency threshold of 0.05%. The set
contains 34 HLA-A, 60 HLA-B, and 27 HLA-C allotypes. Next, binding
affinity to a set of 50,000 random natural 9-mer peptides was predicted for
each of these HLA molecules using NetMHCpan (version 2.8) (4, 5) that
has been trained on data, including the HLA-C–binding data described in
this work.
The functional distance between two HLA molecules was calculated
as described for the MHCcluster method (24) (version 2.0, using
NetMHCpan version 2.8 as prediction method). In short, the similarity
between any two molecules is estimated from the correlation between the
union of the top 10% strongest binding peptides for each allele. This sim-
ilarity is 1 when the two molecules have a perfect binding specificity overlap
and negative when the two molecules share no specificity overlap. The
distance between two molecules is next defined as 1 2 similarity. Using this
distance measure, a distance matrix is calculated containing the distance
between any two HLA molecules. The distance matrix is converted to an
unweighted pair group method with arithmetic mean distance tree. To esti-
mate the significance of the MHC distance tree, a large set of distance trees is
generated using the bootstrap method, and a final tree is summarized in the
form of a “greedy” consensus tree with corresponding branch bootstrap
values.
Sequence logos describing the bindingmotif of each HLAmolecule were
generated using the top 1% highest scoring predictions as input to the
Seq2Logo sequence logo generator (24) with default options.
CTL responses in HLA-C*07:01 transgenic mice
Ficoll-purified splenocytes from HLA-C*07:01 transgenic mice were
assayed for CD8+ T cell responses following peptide and DNA immuni-
zation by an IFN-g ELISPOT assay as described previously (26).
Donors
The study of donor immune responses was approved by the Committees on
Biomedical Research Ethics of the Capital Region (De Videnskabsetiske
Komiteer for Region Hovedstaden), and informed written consent was
obtained. Blood samples were obtained from healthy yellow fever vaccinees
14–20 d after vaccination. PBMCs were isolated by density gradient
centrifugation using Ficoll-Paque Plus (GE Healthcare Europe, Brøndby,
Denmark) and stored until use at 2150˚C. Chromosomal DNA was iso-
lated from and typed for HLA-A/B/C and HLA-DR/DQ/DP using
sequence-based typing (Genome Diagnostics, Utrecht, The Netherlands).
Tetramer staining
Tetramers of HLA-C*03:04 were produced as previously described (20).
Briefly, biotinylated recombinant HLA class I H chains were diluted into
a reaction buffer containing 50 mM Tris-maleate (pH 6.6), 0.1% Lutrol
F68 NF (BASF, a surfactant compatible with cellular use), and excess
of b2m and peptide and incubated for 48 h at 18˚C. To tetramerize
the resulting peptide–HLA–I monomers, streptavidin-R–PE or streptavidin-
allophycocyanin was sequentially added over 60 min at a 1:4 molar ratio of
streptavidin to peptide–HLA-I monomers. PBMCs (106) were resuspended in
25 ml PE- and allophycocyanin-conjugated tetramer and incubated for 20 min
at room temperature followed by 30 min incubation with a mixture of anti-
CD3, anti-CD4, anti-CD8, and anti-CD56 Ab (BioLegend, San Diego, CA).
Data analysis
All data handling and nonlinear regression analyses were done using
Microsoft Office Excel 2007 and GraphPad Prism. Flow cytometry data
were analyzed by FACSDiva software.
Results
Determining MHC-I peptide-binding motifs by combining
PSCPL with an SPA-based dissociation assay
We have recently published a MHC-I dissociation assay based on
recombinant biotinylated MHC-I H chain and radiolabeled b2m
(23). The strength of this assay lies in that it requires no labeling
of the peptide in question, it is very robust and accurate, and it has
a high throughput allowing the measurement of 384 distinct dis-
sociation curves in parallel in a single experiment. We reasoned
that the nature of this assay would make it suitable for PSCPL
analysis (17) of the peptide-binding specificity of any MHC-I
molecule. In a PSCPL-based specificity analysis of peptide–
MHC-I interaction, all possible peptides of a given size (in this
case 9 mers) are represented by a systematic set of sublibraries.
For each sublibrary, one amino acid in one position is kept con-
stant, whereas the remaining positions contain mixtures of amino
acids. The PSCPL approach yields a complete representation of
MHC-I specificity encompassing all positions (including primary
and secondary anchors) and all possible residues (i.e., all 20
naturally occurring residues, including favored and disfavored
amino acids). The resulting description of MHC specificity can be
represented as a quantitative position-specific scoring matrix,
which for every peptide position gives the RB of each of the 20
naturally occurring amino acids (as detailed in Materials and
Methods). Originally, Falk et al. (27) defined an AP as a position
that reveals “a strong signal for only one residue, or alternatively,
if a position is occupied by a few residues with closely related side
chains.” Operationally, the AP values are calculated as the sum of
squared deviations of RB values for a given position. This readily
indicates the location of anchor positions and their relative im-
portance. Traditionally, affinity measurements of each PSCPL
sublibrary have been used to determine PSCPL matrices (17, 28,
29). To examine whether dissociation measurements could be used
to obtain identical or similar data, we initially compared affinity-
versus dissociation-based PSCPL matrices representing the spec-
ificity of the well-characterized HLA-A*02:01 allotype (Table I).
Predictably, the enormous diversity of peptides present in a
PSCPL sublibrary led to a multiphase dissociation curve (data
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not shown), which complicates any analysis based on using the t1/2
as the parameter of dissociation. Therefore, we tested different
parameters including 1) the signal at time 0 (Y0), 2) the half-life
determined from the first 9 h of dissociation as fitted by GraphPad
Prism, 3) integrating the counts over the first 24 h dissociation
period (normalized for Y0), and 4) integrating the counts over the
first 24 h dissociation period (without normalization). The latter
measure gave (sublibrary by sublibrary, position by position)
a nearly perfect match with the results obtained using affinity
measurements (Table I). Thus, the well-known HLA-A*02:01
specificity with positions 2 and 9 as anchor positions (preferred
residues Leu and Met in position 2; preferred residues Val, Leu,
Ile, and Met in position 9) was revealed by the stability-driven
PSCPL analysis using integrated counts without Y0 normalization.
This is perhaps not surprising given that this read-off mode cap-
tures both complex formation and the subsequent dissociation
phase. In contrast, both the integrated counts normalized for Y0
and the fitted half-life solely capture dissociation, and these
stricter measures reduced the signals, making it much more dif-
ficult to discern motifs (data not shown).
Determining the peptide-binding motif of 16 HLA-C allotypes
Using the dissociation-driven PSCPL analysis, we analyzed the
specificity of 17 recombinant HLA-C molecules: HLA-C*01:02,
-C*02:02, -C*03:02, -C*03:03, -C*03:04, -C*04:01, -C*05:01,
-C*06:02, -C*07:01, -C*07:02, -C*07:04, -C*08:01, -C*08:02,
-C*12:03, -C*14:02, -C*15:02, and -C*16:01. For 16 of these 17
HLA-C molecules, distinct peptide-binding specificities were
readily revealed, whereas low or inconsistent signals were ob-
tained for one molecule, HLA-C*01:02. The resulting motifs are
Table I. Determining the peptide-binding motifs of MHC-I allotypes using PSCPL
Residue
Amino Acid Position in Peptide
1 2 3 4 5 6 7 8 9
Peptide–MHC-I affinity
A 1.2 0.5 1.0 0.2 1.1 1.1 0.8 1.0 1.9
C 0.7 0.1 0.2 1.0 0.6 0.6 0.9 1.0 0.2
D 0.0 0.0 1.1 2.8 1.4 1.4 0.5 0.8 0.0
E 0.1 0.0 0.4 2.6 1.4 0.7 1.0 1.6 0.0
F 3.8 0.2 2.9 0.0 1.5 1.4 3.2 1.2 1.0
G 1.1 0.3 0.6 1.1 1.9 0.7 0.1 0.9 0.5
H 0.9 0.1 0.2 0.9 1.1 0.7 0.4 0.7 0.0
I 0.6 1.8 1.1 0.5 0.9 1.5 1.7 0.4 2.5
K 1.2 0.1 0.2 0.8 0.5 0.0 0.2 0.5 0.0
L 0.8 5.0 1.2 0.5 0.8 1.7 0.9 1.1 2.7
M 1.4 6.9 2.4 0.9 0.9 1.0 1.5 0.9 2.1
N 0.4 0.1 1.0 0.6 0.9 1.5 0.6 0.9 0.1
P 0.1 0.0 0.6 1.9 0.6 1.8 1.2 2.2 0.1
Q 0.4 1.8 1.0 1.2 0.8 0.5 1.0 1.3 0.1
R 1.4 0.1 0.2 0.7 0.8 0.4 0.3 0.9 0.1
S 1.1 0.1 1.3 0.6 0.6 1.2 0.6 0.7 0.1
T 0.7 1.0 0.9 1.1 0.8 0.6 0.9 1.0 0.1
V 1.1 1.6 0.6 0.8 1.0 1.2 0.6 0.6 8.4
W 0.6 0.1 1.2 0.4 1.4 0.8 1.7 0.6 0.0
Y 2.5 0.2 1.8 1.3 0.8 1.0 1.9 1.4 0.1
Sum 20 20 20 20 20 20 20 20 20
AP value 14 64 10 10 2 4 10 3 74
Peptide–MHC-I
complex dissociation
A 1.01 0.7 1.7 1.2 1.1 1.2 1.5 1.2 2.2
C 0.5 0.5 1.6 1.1 0.9 0.7 1.4 1.2 0.5
D 0.0 0.0 1.3 2.7 0.8 0.7 0.4 0.5 0.0
E 0.0 0.0 0.2 1.9 0.7 0.8 0.8 1.7 0.0
F 2.3 0.2 2.5 0.8 1.3 0.9 2.7 1.5 0.4
G 0.8 0.2 0.7 0.0 1.3 0.5 0.3 1.0 0.2
H 0.7 0.0 0.7 1.3 1.2 1.0 1.3 0.9 0.0
I 0.7 1.9 0.7 0.3 0.8 1.6 0.4 0.4 2.2
K 1.8 0.1 0.1 0.7 1.0 0.6 0.1 0.5 0.1
L 1.1 6.4 1.7 0.2 0.8 1.4 0.9 0.5 4.2
M 1.5 5.6 2.7 0.4 0.8 1.0 1.5 0.3 2.4
N 0.4 0.1 1.0 1.1 0.9 1.6 0.8 0.5 0.0
P 0.0 0.1 0.4 1.3 0.6 1.7 2.3 2.6 0.1
Q 0.4 1.5 0.9 1.0 0.6 1.3 0.8 1.1 0.0
R 1.4 0.1 0.1 0.7 1.2 0.5 0.3 0.8 0.0
S 1.1 0.2 1.2 1.0 0.9 0.9 0.5 0.9 0.4
T 1.1 0.9 1.1 1.1 1.0 0.5 1.4 1.3 0.8
V 1.2 1.3 0.5 0.6 0.7 0.9 1.3 0.6 6.4
W 0.9 0.1 0.4 0.9 1.9 0.7 0.6 0.6 0.0
Y 2.9 0.1 0.7 1.5 1.5 1.5 0.7 1.9 0.0
Sum 20 20 20 20 20 20 20 20 20
AP value 11 62 10 7 2 3 9 7 56
The peptide-binding motif of HLA-A*02:01 was determined via nonameric PSCPL analysis either by peptide–MHC-I affinity measurement or
peptide–MHC-I complex dissociation. Residues with RB values larger than 2 are in terms of peptide binding considered favored (bold numbers) in the
given position, residues with RB values ,0.5 are considered disfavored (italic numbers), and residues with 0.5 , RB , 2.0 are accepted (numbers in
regular font). Both methods capture the well-described peptide-binding motif of the HLA-A*02:01 allotype, having strong anchors in peptide positions 2
and 9 with preference for Leu/Met and Leu/Val, respectively. RB values are shown.
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shown as LOGO representations in Fig. 1 and the full peptide-
binding matrix representations are shown in Supplemental
Table I). At first glance, the overall shape of the motifs of these
HLA-C allotypes appeared very similar to those seen for HLA-A
and -B allotypes. In terms of the number and distribution of an-
chor positions, all motifs featured a pronounced primary anchor
position at the C-terminal, and most motifs also featured a more or
less pronounced primary anchor position at P2 and/or P3 as well
as some secondary anchor positions scattered in P1, P2, P3, and
P7; the only exception appeared to be HLA-C*14:02, which almost
exclusively exhibited C-terminal specificity. In terms of which
amino acid residues were present in these primary anchor posi-
tions, the primary C-terminal anchor position of all these HLA-C
allotypes contained a restricted repertoire of hydrophobic and
aromatic residues such as Phe, Ile, Leu, Met, Val, and Tyr. In
contrast, the primary P2/P3 anchor positions contained a much
more variable repertoire of hydrophobic, polar, or charged (both
positively and negatively) amino acids (summarized in Table II).
Secondary anchors were observed at P1, P2, P3, and P7 (Table II).
High-affinity peptide binders predicted by PSCPL matrices
A PSCPL-derived HLA-I motif represents the combined effect of
all the peptides of the individual PSCPL sublibraries, which each
encompass billions of different peptides. In reality, peptide binding
to HLA-I involves components of correlated effects where one
amino acid in one position may affect the specificity at other
positions. Correlated effects cannot be captured by a PSCPL matrix
approach, which inherently assumes that all amino acids in all
positions are recognized independently of the amino acids present
in all other positions (also known as “independent binding of side-
chains”) (30). In contrast, neural networks (and other higher order
data-mining methods) are ideally suited to capture and predict
peptide–HLA-I binding including any correlated effects. However,
the development of neural networks is dependent on the avail-
ability of a large body of data representing many different single
peptide-binding events (31). To generate single peptide-binding
data and support the development of neural networks, we used
the PSCPL matrices to identify peptides that were predicted to
bind to the different HLA-C allotypes. Over the years, we have
collected ∼9000 nonamer peptides from various sources. Multi-
plying the relevant RB values of the different amino acids in the
different positions, we predicted the binding of each peptide/HLA-
C allotype combination. For each HLA-C allotype, we then ranked
the peptides, selected the 100 highest scoring peptides, and mea-
sured the affinity of binding of each peptide using a previously
published high-throughput peptide-binding assay (25). Eight
FIGURE 1. HLA-C allotypes exhibit classical MHC-I peptide-binding motifs. The peptide-binding motifs of 16 HLA-C allotypes were determined by
SPA-driven PSCPL analysis using a nonameric peptide library. Binding motifs are represented as logos generated from peptide-binding matrices using the
Seq2Logo server (24). The height of each letter indicates the information content, that is, larger letters indicate residues having more impact on binding in
the given position, be it positive or negative. Amino acids plotted on the positive y-axis contribute positively to peptide binding, whereas amino acids
plotted on the negative y-axis contribute negatively to peptide binding. The total height of a given position indicates the information content, and thus higher
stacks represent amino acid position important for peptide binding. Each logo is an average of two independent experiments.
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HLA-C allotypes were included in this analysis (i.e., HLA-
C*03:03, -C*04:01, -C*05:01, -C*06:02, -C*07:02, -C*12:03,
-C*14:02 and -C*15:02). Overall, this selection method was very
successful in identifying binding peptides (Supplemental Table IIA).
Thus, the frequency of binders with a KD , 500 nM, which is
commonly regarded as the threshold for a peptide–HLA-I combi-
nation being immunogenic, was 71–85% for all HLA-C allotypes
studies, except for HLA-C*04:01 (18%). The fewer number of
binders found for HLA-C*04:01 is likely due to a bias in our
peptide repository, which has been built to match HLA-I spe-
cificities of interest over the years. These results are in agree-
ment with observations by other groups using PSCPL-based
peptide selection (17).
Additional peptide binders predicted by NetMHCpan
We reasoned that the pan-specific NetMHCpan predictor might
identify peptides that have not been captured by, or do not conform
to, PSCPL-generated motifs and therefore could expand our se-
lection of peptides with some that are particularly valuable and
information-rich. To this end, we selected an additional set of
peptides from our nonamer peptide repository, but this time we
searched for peptides with a high NetMHCpan but a low PSCPL
ranking and measured the binding of these peptides. For HLA-
C*04:01, C*05:01, -C*06:02, and -C*07:02, most peptides se-
lected according to this stringent strategy were nonbinders, and
the binders, which were identified, were only intermediary bind-
ers, suggesting that for these HLA-C allotypes the PSCPL ma-
trices had already captured most of the information about pep-
tide binders. For HLA-C03:03, -C12:03, -C*14:02, and -C*15:02,
however, NetMHCpan managed to identify additional, non–
matrix-conforming peptide binders, many of which were strong
binders. This is particularly obvious for HLA-C*12:03 and HLA-
C*14:02, where 75 and 84%, respectively, of the additional pep-
tides identified by NetMHCpan were binders (Supplemental
Table IIB). This demonstrates that for these latter HLA-C allo-
types, NetMHCpan captured valuable information that had not
been captured by the PSCPL matrices.
Improving NetMHCpan predictions of HLA-C binding
Overall, the combined strategy described above assured that both
unbiased (PSCPL) and “experienced” (NetMHCpan) components
were involved in the important selection of informative peptides
needed for efficient neural network development. The new HLA-
C–binding data were added to the data that originally were used
to generate NetMHCpan (version 2.3, predominantly generated
from HLA-A– and HLA-B–binding data), and the predictor was
retrained. The ability to identify peptides known to bind to HLA-
A, -B, and -C according to the SYFPEITHI database of natural
HLA bound and/or immunogenic peptides was used to validate the
updated predictor and to compare it with its predecessor. With
respect to predicting peptide binding to HLA-C, the performance
of the updated NetMHCpan method was significantly improved
when the new HLA-C data were added to the training data
(Fig. 2). In contrast, the prediction of peptide binding to HLA-A
and -B was unaffected. For HLA-C, the predictive performance
Table II. Peptide anchor positions and preferred anchor residues of HLA-C allotypes identified from
nonameric PSCPL analysis
Allotype
Peptide Position
P1 P2 P3 P4 P5 P6 P7 P8 P9
HLA-C*02:02 FY A F LMVY
HLA-C*03:02 A F LM Y
HLA-C*03:03 FY AS FILMV
HLA-C*03:04 Y AS FILM
HLA-C*04:01 FY FWY D FILM
HLA-C*05:01 Y AS D FILMV
HLA-C*06:02 FY RY AFY KQR ILMV
HLA-C*07:01 KR R FM H I FWY F LM Y
HLA-C*07:02 FY RY FWY F LM Y
HLA-C*07:04 Y R F F LM
HLA-C*08:01 FY A LMV
HLA-C*08:02 AS D N FILM
HLA-C*12:03 Y A Y FILMVY
HLA-C*14:02 F LMV
HLA-C*15:02 KRY NST H L ILMV
HLA-C*16:01 AF R F LM Y
Sixteen HLA-C molecules were analyzed for peptide-binding specificity by SPA-driven PSCPL analysis. Amino acid
residue preferences are indicated in standard single-letter amino acid code. An RB value of .2 was used as a threshold for
preferred binding. Boldface letters denote a primary anchor residue; italic letters denote an auxiliary anchor.
FIGURE 2. Improvement of HLA-C–binding prediction tools. The
NetMHCpan prediction method was enriched with HLA-C binding data
for eight HLA-C allotypes (HLA-C*03:03, -C*04:01, -C*05:01, -C*06:02,
-C*07:02, -C*12:03, -C*14:02, and -C*15:02). Comparison of perfor-
mance efficacy, measured by the AUC, of the previous version of the
NetMHCpan predictor with a new version updated with HLA-C–binding
data shows that enrichment with HLA-C–binding data improved the per-
formance of peptide–HLA-C-binding prediction.
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measured in terms of the AUC for a set of 77 HLA-C ligands
described in the SYFPEITHI database (www.syfpeithi.de) in-
creased from 0.87 to 0.97, improving the performance of HLA-C
predictions to a level comparable to those of HLA-A and HLA-B
(Fig. 2). This improvement is highly significant (p , 1026, bi-
nomial test excluding ties).
Evaluating HLA-C binding
The improved NetMHCpan predictor (version 2.8) was subse-
quently used to examine the peptide-binding specificities of the
HLA-C isotype. Initially, the most frequent members of HLA-A,
-B, and -C isotypes were compared. One hundred twenty-one
different HLA-I allotypes with an allele frequency of .0.05%
in the European population were extracted from the dbMHC da-
tabase: 34 HLA-A, 60 HLA-B, and 27 HLA-C allotypes. The
functional distance between any two HLA-I allotypes was calcu-
lated using the MHCcluster method (32) as described in Materials
and Methods. This analysis revealed that the peptide-binding
specificities of the HLA-C isotype are distinctly different from
those of HLA-A or -B isotypes (colored red, green, and blue for
HLA-A, -B, and -C, respectively, Fig. 3). Furthermore, isotype-
specific histograms of the pairwise distances between the 34 HLA-
A, 60 HLA-B, and 27 HLA-C allotypes (colored red, green, and
blue for HLA-A, -B, and -C, respectively, Fig. 4) revealed that the
HLA-C isotype has a more narrow functional diversity, that is, that
it presents a less diverse peptide repertoire than do the HLA-A or
HLA-B isotypes (Fig. 4). To further illustrate this, we estimated
the repertoire of peptides presented by the HLA-A, -B, and -C
isotypes. From a set of 50,000 random natural 9-mer peptides, we
extracted the 1% highest scoring peptides for each of the 34, 60,
and 27 prevalent members of the HLA-A, -B, and -C isotypes,
respectively, and then identified the number of unique peptides per
isotype, that is, 5491, 6376, and 2624, for the HLA-A, -B, and -C
isotypes, respectively. Compared to the HLA-A and -B isotypes, it
would appear that the HLA-C isotype binds a more distinct and
limited part of the universe of peptides.
Next, we extracted a representative set of HLA-C allotypes and
constructed a tree of the peptide-binding specificities of the HLA-C
isotype. To obtain a nonredundant representation of HLA-C,
we extracted representative allotypes by homology reduction ad
modum Hobohm II (33). The resulting 86 HLA-C allotypes were
analyzed as described above using the MHCcluster method and
FIGURE 3. In silico functional clustering of 121 HLA-A, -B, and -C molecules. Using the updated NetMHCpan predictor to cluster 121 common HLA-I
allotypes (34 HLA-A, 60 HLA-B, and 27 HLA-C) according to predicted binding motif shows that allotypes of the HLA-C isotype have distinctly different
peptide-binding specificities from those of the HLA-A and HLA-B isotypes. The clustering is calculated from the predicted binding of a set of 50,000
random natural 9-mer peptides using 100 bootstrapped distance trees. Sequence logos are added to the plot displaying the predicted binding motif for
a representative allotype for each cluster in the tree. Tree and sequence logos are calculated as described in Materials and Methods.
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illustrated as an unweighted pair group method with arithmetic
mean distance tree (Fig. 5, including LOGO representation of
the peptide-binding specificity of allotypes representing the
main branches). This analysis illustrates the limited functional
(i.e., peptide-binding specificity) diversity of the HLA-C isotype.
In particular, the strong preference for a hydrophobic residue at P9
is a shared feature of all allotype members of the HLA-C isotype,
a requirement that can be viewed as a prerequisite for being an
HLA-C–binding epitope. Once that universal requirement is met,
the functional diversity is primarily seen in less influential posi-
tions of the motif such as the recognition of the P2/P3 anchor
residues. As shown, the tree is largely divided into two major
partitions: one partition that prefers Tyr and Phe or Arg at P2 (seen
to the left of the tree, Fig. 5), and another partition that prefers
Ala, Ser, and Thr at P2 or Asp and Glu at P3 (seen to the right part
of the tree, Fig. 5).
The HLA-C isotype is unique in the sense that virtually all HLA-
C allotypes express either the C1 or C2 KIR ligands, which are
determined by the presence of Asn or Lys, respectively, in position
80 of the HLA-C (the only exception being HLA-C*07:115, which
expresses an Asp in position 80). It is not known to what extent
this essentially dimorphic position affects peptide binding and
the subsequent generation of the C1/C2 epitopes (34). Being in
close proximity to the bound peptide, position 80 may potentially
affect the peptide-binding specificity directly. Indeed, position 80
is part of the HLA-I pseudosequence that is used to generate the
NetMHCpan predictor (5). Because the predictor allows the sub-
mission of custom sequences, we reasoned that it might empower
a systematic analysis of the effect of virtual Asn80Lys (i.e., C1 to
C2 epitope) or Lys80Asn (i.e., C2 to C2 epitope) single-point
mutations and thereby shed light on the possible contribution of
the C1/C2 epitope dimorphism to the peptide-binding specificity
of the corresponding HLA-C allotypes. The Asn80 (i.e., the C1
epitope) and Lys80 (i.e., the C2 epitope) are expressed in 47 and 39
of the 86 representative wild-type HLA-C allotypes included in
this study, respectively. Similar to the MHCcluster approach de-
scribed above, we extracted the 1% top predicted peptide binders
from 50,000 random natural 9-mer peptides for the 47 wild-type
C1-expressing HLA-C allotypes and the corresponding Asn80Lys
single-point mutations, as well as for the 39 wild-type C2-
expressing HLA-C allotypes and the corresponding Lys80Asn
single-point mutations. Only 1.1 and 1.3% of the resulting pep-
tides differed between the wild-type and the virtual single point-
mutated molecules, suggesting that the C1/C2 dimorphism does
not contribute much to the peptide-binding specificity of the HLA-
C isotype.
Using the improved predictors to identify HLA-C–restricted
peptides
In the past, the prediction of HLA-C–restricted epitopes has been
hampered by the relative lack of data and accurate predictors
relevant for HLA-C allotypes. We have recently generated an
HLA-C*07:01 transgenic mouse strain expressing the HLA-
C*07:01 a1a2 H chain domains fused to a mouse a3 domain and
covalently linked to human b2m. Initially, we used published
HLA-C*07:01–restricted epitopes (35–37) to test the HLA-
C*07:01 restricting capacity of transgenic mice. These mice were
immunized either 1) with peptide epitopes formulated with
a helper epitope in IFA and injected s.c., or 2) with epitope-
encoding DNA vaccines and injected i.m. In either event, we
would detect epitope-specific CD8+ T cell responses using an
IFN-g ELISPOT assay. However, three of three previously pub-
lished epitopes failed to induce CD8+ T cell responses whether
immunized with peptide or through DNA vaccination. This raises
the question of the sensitivity of this transgenic system. Using the
improved predictor we noted that none of these peptides would
be predicted to be binders to HLA-C*07:01 according to the
work presented in this study (Table III). We have recently con-
firmed previous reports stating that peptide–HLA-I stabil-
ity, rather than affinity, is indicative of immunogenicity (38).
Therefore, we selected the six most stable HLA-C*07:01 binders
from the panel of HLA-C*07:01–binding peptides identified in
this study and used these to immunize HLA-C*07:01 transgenic
animals using either the peptide or DNA immunization strategies.
All six of these in silico predicted and biochemically verified
high-stability binders were able to induce strong CD8+ T cell
responses (Table III; note that two of these six epitopes have
been reported previously; see Ref. 26). Thus, the HLA-C data and
predictors presented in the present study appear to capture the
peptide-binding activity and specificity of HLA-C allotypes,
FIGURE 4. HLA-C allotypes bind a less diverse set of peptides compared with HLA-A and HLA-B allotypes. Normalized histograms of HLA intraloci
functional similarity distances are shown. The figure displays the probability (p) of observing a given functional distance (d) between different HLA
molecules within each of the three loci (HLA-A, HLA-B, and HLA-C). Functional distances between two HLA molecules were calculated as described in
the text using the MHCcluster similarity measure. Distances were normalized so that the maximal distance for any HLA pair was 1, and the minimal
distance was 0. The histograms were calculated from the 121 HLA molecules included in Fig. 3.
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resulting in improved predictions of immunogenic epitopes (at
least for HLA-C*07:01).
Using recombinant HLA-C molecules to generate tetramers
and label lymphocytes
Finally, we wanted to examine whether our recombinant HLA-C
preparations are suitable for tetramer generation. To this end, we
generated HLA-C tetramers to evaluate a yellow fever NS2A4–13
(HAVPFGLVSM)–specific response, which have been observed in
HLA-C*03:04+ yellow fever vaccinees (to be reported elsewhere).
HLA-C*03:04 tetramers incorporating either the NS2A4–13 or
a negative control peptide were generated. Both peptides could
bind to HLA-C*03:04 and support tetramer formation (data not
shown); however, only the NS2A4–13/HLA-C*03:04 tetramer
could label cells in the lymphocyte gate as detected by flow
cytometry. As shown in Fig. 6, the specific tetramer labeling did
not only involve a CD8+ T cell population, but also a prominent
CD32, CD42, CD82, CD56+ population, suggesting a NK cell
FIGURE 5. In silico functional clustering of 86 representative HLA-C allotypes. Eighty-six representative HLA-C allotypes were clustered according to
predicted binding motif. The clustering was calculated from the predicted binding of a set of 50,000 random natural 9-mer peptides using 100 bootstrapped
distance trees. Sequence logos are added to the plot displaying the binding motif for a representative molecule for each cluster in the tree. The eight HLA-C
molecules characterized with binding data are highlighted in red. Tree and sequence logos are calculated as described in Materials and Methods.
Table III. HLA-C*07:01 transgenic mice have CD8+ T cell responses against HLA-C*07:01–binding peptides of high stability
Peptide Sequence
HLA-C*07:01–Binding Prediction
pHLA-I Stability,
t1/2 (h) References
NetMHCpan
PSCPL
Scoreb
CD8+ T Cell IFN-g Responses (INF-g/106 Cells)
% Ranka Binding Level DNA Immunization Peptide Immunization
PLADLSPFA 50.00 Nonbinder 0 ND 0/0/0/0 0/0/0/0 (26, 35)
EGDCAPEEK 50.00 Nonbinder 0 ND 0/0/0/0 0/0/0/0 (26, 36)
RNGYRALMDKS 50.00 Nonbinder N/Ac ND 0/0/0/0 0/0/0/0 (26, 37)
RRRPVTRPL 0.12 Strong binder 85 16.2 33/33/24/1 619/599/177/0 (26)
RRARYWLTY 0.30 Strong binder 81 27.2 273/246/42/9 643/640/133/97/92 (26)
RRMATTFTF 0.12 Strong binder 267 34.6 338/185/125/101 317/225/69/21/0
RRNDGVVQY 0.25 Strong binder 99 16.3 17/0/0/0 308/289/189/50/34
RYSGFVRTL 0.25 Strong binder 50 17.7 427/371/56/5 388/185/7/5
SRPLVSFSF 1.50 Weak binder 40 22.4 329/318/20/3 221/123/49/38
Predicted HLA-C*07:01–binding peptides of high stability and previously published HLA-C*07:01–restricted peptides were used to immunize HLA-C*07:01 transgenic
mice. IFN-g T cell responses were assayed by ELISPOT following peptide and DNA immunization. Peptide-binding predictions were done using the updated NetMHCpan
server, and PSCPL scores were calculated by multiplication of the individual RB value from each peptide position using the PSCPL-derived HLA-C*07:01–binding matrix. The
peptides reported were selected from a large repository of peptides collected for many different purposes. The pHLA-I complex stability was measured by an SPA-based pMHC-I
dissociation assay. ND, not determined.
aValues of ,0.5 are considered high-affinity interactions, 0.5–2 medium-affinity interaction, and values of .2 are considered of low affinity or nonbinding.
bPSCPL scores are calculated by multiplication of the PSCPL-derived RB value for each peptide position (see Materials and Methods); higher values predict higher affinity.
cNot available. PSCPL prediction scores are based on a nonamer PSCPL and can thus only be calculated for nonameric peptides.
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origin of the latter population. Indeed, gating on tetramer+ lym-
phocytes suggested the existence of at least two tetramer+ sub-
populations: a CD8+/CD562 population and a CD8-/CD56int
population accounting for 4 and 87% of the tetramer+ cells, re-
spectively. We suggest that the former population consists of
classical CD8+ CTLs whereas the latter consists of NK cells;
however, a more detailed analysis of these phenotypic character-
istics is beyond the scope of the present study. Suffice it to say that
these HLA-C tetramers can label lymphocytes in a peptide-
dependent manner.
Discussion
Information about peptide binding to HLA-C is somewhat limited.
Thus, as of March 2014, ,1% of the HLA-I ligand data and ,1%
of the HLA-I allotypes hosted at the authoritative IEDB database
originated from the HLA-C isotype; peptide-binding predictions
perform poorer for the HLA-C isotype than for the HLA-A and -B
isotypes; and only three published structures of HLA-C complexes
exist in the PDB structure database (1QQD, 1IM9, and 1EFX) and
they are all at a relatively low level of resolution (2.7–3.0 A˚). In
this study, we present a systematic analysis of the peptide-binding
specificity of the HLA-C isotype. We have selected a panel of the
most commonly expressed HLA-C allotypes and generated them
as recombinant molecules, developed a general approach to un-
cover the peptide-binding specificity of these molecules, generated
peptide-binding data for several different HLA-C allotypes, and
updated the NetMHCpan method for MHC peptide-binding pre-
dictions. The updated predictor is improved considerably with
respect to HLA-C predictions and is now at par with predictions
for HLA-A and -B isotypes. Being pan-specific, this predictor can
be applied to all HLA-C allotypes irrespective of whether exper-
imental data exist for a specific allotype of interest. In other words,
the improved NetMHCpan predictor can be used to describe the
specificity of the entire HLA-C isotype.
The motifs identified in the present study largely match those
previously described for HLA-C*03:04 (9), HLA-C*06:02 (39,
40), HLA-C*07:01 (40), and HLA-C*07:02 (39), supporting the
notion that the approach taken in the present study yields an ac-
curate representation of the peptide-binding properties of HLA-I
molecules. For all HLA-C allotypes, whether tested experimen-
tally or inferred bioinformatically, we observed the presence of
a strong and dominant C-terminal primary anchor position, which
encompassed a rather restricted repertoire of hydrophobic and
aromatic amino acid residues (Phe, Ile, Leu, Met, Val, and Tyr).
Whereas a dominant C-terminal anchor position is also commonly
observed within the HLA-A and -B isotypes, for these later iso-
types the amino acid composition of this anchor position is often
more diverse. This explains, at least partially, the more limited
peptide-binding repertoire of the HLA-C isotype compared with
the HLA-A and -B isotypes. For most HLA-C allotypes, we also
observed the presence of primary P2 and/or P3 anchor positions.
Encompassing a greater repertoire of amino acids than the C-
terminal anchor position, the P2/P3 anchor positions contribute
with most of the differences in peptide-binding specificity ob-
served within the HLA-C isotype. Using the P2/P3 specificity as
a token, one can identify at least four major groups of HLA-C
specificities: Ser/Ala/Thr in P2 (e.g., HLA-C*03:03), Tyr/Phe in
P2 (e.g., HLA-C*04:01 and HLA-C*14:02), Asp/Glu in P3 (e.g.,
HLA-C*05:01), and Arg in P2 (e.g., HLA-C*07:01).
We have analyzed the motifs of HLA-C more systematically and
in more detail, anchor position by anchor position. All HLA-C
allotypes studied share a preference for aromatic and/or hydro-
phobic amino acids such as Phe, Ile, Leu,Met, Val, and Tyr at the C-
terminal anchor position (Supplemental Table III). All molecules
accept Phe, Ile, Leu, Met, and Val at the C-terminal position (RB
values . 0.5), whereas Tyr is only accepted by selected allotypes
(HLA-C*02:02, -C*03:02, -C*06:02, -C*07:01, -C*07:02, -C*12:
03, -C*14:02, and -C*16:01). Of the polymorphic HLA residues
interacting with the peptide C-terminal position (residues 74, 77,
80, 81, 84, 95, 97, 116, 118, 143, and 147 according to the
NetMHCpan pseudosequence defined by a 4 A˚ threshold) (5),
residues 77, 80, 95, 97, 116, and 147 are polymorphic among the
HLA-C molecules. The allotypes accepting a C-terminal Tyr all
express Ser at position 116 (Supplemental Table III), whereas
allotypes having Tyr116 (HLA-C*03:03 and -C*03:04), Phe116
(HLA-C*04:01, -C*05:01, -C*07:04, -C*08:01, and -C*08:02), or
Leu116 (HLA-C*15:02) disfavor the presence of Tyr at the peptide
C-terminal position (RB values , 0.5). Residue 116 of the MHC-I
molecule is placed at the bottom of the P9 pocket, greatly influ-
encing the peptide-binding motif of the MHC-I molecule (41). In
lieu of structural data for HLA-C, one can make a comparison
with a similar observation that has been reported for HLA-B*35:
01 (Ser116) and HLA-B*35:03 (Phe116), where HLA-B*35:01
allows binding of a C-terminal Tyr, whereas HLA-B*35:03 cannot
accommodate a Tyr residue in the F pocket (41).
FIGURE 6. pHLA-C tetramer staining of CD8+ T lymphocytes. PBMCs
from a yellow fever–vaccinated donor were stained with Abs against cell
surface markers CD3, CD4, CD8, and CD56 and with two specific tet-
ramers, that is, HLA-C*03:04-NS5477–485 (YMWLGARYL) (A and B) and
HLA-C*03:04-NS2A4–13 (HAVPFGLVSM) (C–E). The results in (A)–(D)
are gated for the total lymphocyte population whereas (E) is gated for all
tetramer+ lymphocytes.
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Strong anchors were also observed at the N-terminal end of the
peptide, namely at P2 and/or P3 (Supplemental Table IV). This is
a common positioning of a primary anchor in the HLA-C isotype,
as well as in the HLA-A and -B isotypes. Concerning P2, both
HLA-C*03:03, HLA-C*03:04, and HLA-C*12:03 have an anchor
position at P2 featuring either Ala or Ser (Supplemental Tables IC,
ID, IM, and IV). Of the polymorphic residues that interact
with P2 according to the pseudosequence (5), HLA-C*03:03,
HLA-C*03:04, and HLA-C*12:03 share a Tyr9, Ala24, Tyr99 motif
(Supplemental Table IV), where the Tyr9 significantly restricts the
size of the P2 pocket (42) favoring Ala (9, 39) and, as shown in the
present study, the Ser in the P2 pocket. The Tyr9, Ala24, Tyr99
motif is also present in HLA-C*05:01 and HLA-C*08:02, which
could account for their preference at P2 for Ala or Ser, although
the concurrent presence of the strong Asp anchor residue in P3
seems to lessen the importance of P2, making P2 an auxiliary
anchor in these latter molecules. Of the HLA-C molecules tested,
HLA-C*04:01 has a unique P2 motif favoring aromatic residues
Phe, Trpm and Tyr (Supplemental Table IV), and, although not
confirmed by the PSCPL analysis, NetMHCpan prediction shows
that HLA-C*14:02 shares this motif (Fig. 5, Supplemental
Table IV). The crystal structure of the QYDDAVYKL peptide in
complex with HLA-C*04:01 (PDB 1QQD) shows that the P2 Tyr
fits in a pocket formed by the residues Tyr7, Phe22, Tyr67, and
Phe99, creating a spacious pocket allowing the binding of tyrosine
(43), but rotated differently than in most other HLA-I molecules.
Among the HLA-C molecules studied, residues 7, 22, and 67 are
monomorphic, whereas residue 99 is polymorphic. HLA-C*04:01
and HLA-C*14:02 share the Phe99 phenotype whereas the re-
maining molecules express either Ser99 (HLA-C*07:02 only) or
Tyr99 (Supplemental Table IV), suggesting that this residue could
be important for the P2 specificity of HLA-C molecules. In line
with this, HLA-C*04:01 and HLA-C*14:02 also have Ser at po-
sition 9, whereas other molecules have Tyr9 or Asp9. Position 9 of
the HLA-I molecules is situated at the bottom of the peptide-
binding groove near the N-terminal end of the peptide, and
expressing a bulky amino acid such as Phe or Tyr at residue 9
could restrict the size of the N-terminal–binding pockets.
Concerning P3, HLA-C*04:01, -C*05:01, and -C*08:02 share
a strong preference for Asp (Fig. 1, Supplemental Tables IE, IF,
IL, and IV). In the crystal structure of the QYDDAVYKL peptide
in complex with HLA-C*04:01 (43), the Asp side chain of P3
cannot fit into the small D pocket of HLA-C*04:01, and thus
hydrogen bonds with the peptide backbone and Arg156 (43). This
Arg156 is shared between HLA-C*04:01, -C*05:01, -C*08:02, and
-C*14:02, suggesting a contribution of this residue to the speci-
ficity at the P3 position of HLA-C molecules.
Auxiliary anchor positions were often observed in P1, P2, P3,
and/or P7 (Supplemental Table IV). HLA-C*02:02, -C*03:03,
-C*03:04, -C*04:01, -C*05:01, -C*06:02, -C*07:02, -C*07:04,
-C*08:01, and -C*12:03 have an auxiliary anchor at P1 favoring
Tyr or Phe/Tyr, whereas HLA-C*07:01 and -C*15:02 have an
auxiliary anchor at P1 favoring the positively charged Lys and Arg
residues. Whereas the P1 and P2 pockets of the latter group have
a net negative charge, which confers a preference for positive
amino acids at P1 and P2 (40), the former group has an Asn66
reducing the negative charge of their P1 and P2 pockets
(Supplemental Table IV), which is likely to shift their preference
from positive toward noncharged amino acids. As alluded to
above, HLA-C*05:01 and -C*08:02 show auxiliary preference for
Ala and Ser in position 2. This motif is shared with HLA-C*03:03,
HLA-C*03:04, and HLA-C*12:03; however, the presence of the
strong P3 anchor with preference for Asp likely lessens the sig-
nificance of the residue in P2 for HLA-C*05:01 and HLA-C*08:
02 (Supplemental Table IV). An auxiliary anchor was observed in
P7 where HLA-C*07:01, HLA-C*07:02, and HLA-C*07:04 pre-
fer aromatic amino acids Phe, Trp, and Tyr. These allotypes have
a Leu147–Ala152 motif, compared with a Trp147–(Ala/Glu/Ser)152
motif for the remaining molecules studied. Residues 147 and 152
are located in the a2 helix of the MHC-I molecule facing in to-
ward the peptide-binding groove, and the smaller size of the
Leu147–Ala152 compared with the Trp147–(Ala/Glu/Ser)152 could
indicate the presence of a P7 pocket along the a2 helix in HLA-
C*07:01, HLA-C*07:02, and HLA-C*07:04.
Finally, our functional analysis shows that HLA-C*14:02 has
a very unusual and promiscuous binding motif with no clear
P2 or P3 anchor residues and only a weak P9 primary anchor
(Supplemental Tables III, IV). The lack of a P2 anchor residue is
not obvious because HLA-C*14:02 has a Ser9,indicating that an
aromatic residue could accommodate the P2 pocket of molecule.
The relative lack of anchors may explain the very high frequency
of HLA-C*14:02 binders and may explain why the PSCPL pre-
dictions were less efficient for this allotype.
The HLA-C isotype is unique to hominoids where it has evolved
as the most recent of the HLA-I isotypes (34, 44). The HLA-C is
under two different evolutionary constraints serving both as TCR
ligands for CD8+ T cells and as KIR ligands for NK cells. Both
receptors interact with the outward-facing peptide–MHC complex
and engage both the peptide and the MHC. Thus, there is con-
siderable overlap between the ligands of the two receptors, al-
though the KIR is more focused at the part of the peptide-binding
cleft, which engages the C-terminal end of the peptide, including
the C1/C2 dimorphism at position 80 of the HLA-C molecule, as
well as the P8 and P7 residues of the bound peptide. This raises
the question whether the peptide-binding repertoire of the HLA-C
isotype is affected by the dual requirements of being a TCR and
a KIR ligand. Our data clearly demonstrate that the peptide-
binding repertoire of the HLA-C isotype is much more limited
than are the repertoires of the HLA-A and -B isotypes, and that
this is primarily caused by a restricted repertoire of amino acids at
the C-terminal anchor. Being in the vicinity of the KIR recognition
site, it is tempting to speculate that the KIR ligand requirement is
behind this restriction of the peptide-binding repertoire of the
HLA-C isotype. Another question is whether the C1/C2 dimor-
phism directly affects the peptide-binding repertoire of the HLA-C
isotype. We have exploited the capability of the NetMHCpan
predictor to handle custom MHC-I sequences to perform a sys-
tematic in silico study of the effect of this dimorphism on the
peptide-binding specificity. This analysis showed no sign of gross
alternations of the peptide-binding specificity caused directly by
the C1/C2 dimorphism.
We present a novel method to characterize the HLA-I peptide-
binding specificity based on SPA-driven PSCPL analysis. We show
that an SPA-driven MHC-I dissociation assay can be used in com-
bination with a nonameric PSCPL matrix to obtain an unbiased
rendition of the peptide-binding motif for known as well as unknown
HLA-I molecules. In theory, this approach could be extended to any
MHC-I molecule from any species where the b2m sequence is
a known, and it should be extremely robust because it does not
depend on any preconceived information (e.g., knowledge of an
indicator peptide sequence) or reagents (i.e., availability of a spe-
cific Ab) needed for detecting peptide interaction with the MHC-I in
question. In fact, we have recently exploited this aspect of the ap-
proach to uncover the specificity of panels of bovine, swine, and
bird MHC-I molecules (to be reported elsewhere). In the case of the
HLA-C isotype, we have performed follow-up studies where we
used the HLA-C peptide-binding matrices to assign a rank score to
our panel of .10,000 nonameric peptides. For eight HLA-C mol-
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ecules the 100 highest scoring peptides were tested for binding. In
several cases, we found that ∼70% of these peptides bound with
a KD of ,500 nM. This underscores that PSCPL-driven matrix
analysis is a fast and efficient method to identify binders to HLA
molecules of unknown specificity. To extend the sampling of pep-
tides, we also used the pan-specific NetMHCpan predictor to
identify 100 peptides with high NetMHCpan scores but low PSCPL
scores. It appears that NetMHCpan does capture additional peptide
binders, particularly when the PSCPL has been less successful in
identifying binders. Thus, the two selection methods complement
each other, and we envision that this dual peptide selection principle
could be used as a general method to acquire information-rich
peptide–MHC-I interaction data and develop improved predictors.
Our overall conclusion is that HLA-C isotypes have peptide-
binding features similar to those of a bona fide CTL restric-
tion element. The suite of tools developed in the present study
(recombinant HLA-C molecules and the accompanying binding
assays, motif definitions, predictors, and tetramers) should support
discovery of HLA-C–restricted T cell epitopes and NK targets and
enable a more comprehensive analysis of the usage of HLA-C as
CTL restriction element and as targets of NK cells.
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